Autres langues Kringle Pharma, Inc.

Actions

4884

JP3270790003

Marché Fermé - Japan Exchange Autres places de cotation 08:00:00 13/05/2024			Varia. 5j.	Varia. 1 janv.
538 ^JPY	-1,28 %		-3,76 %	-28,46 %

09/02	Kringle Pharma, Inc. fournit des prévisions de résultats pour l'exercice fiscal se terminant le 30 septembre 2024	CI
2023	Kringle Pharma, Inc. fournit des prévisions de résultats pour l'exercice fiscal se terminant le 30 septembre 2024	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Kringle Pharma, Inc. Provides Earnings Guidance for the Fiscal Year Ending September 30, 2024	09/02
Kringle Pharma, Inc. Provides Earnings Guidance for the Fiscal Year Ending September 30, 2024	28/11
Kringle Pharma, Inc. Completes Its Pre-Ind (Investigation New Drug) Meeting with the U.S. Food and Drug Administration Regarding the Development Plan of Kp-100It, A Lyophilized Formulation of Recombinant Human Hgf, for the Potential Treatment of Acute Spinal Cord Injury	17/11
Kringle's Preclinical Research Shows Encouraging Results for Dual Therapy Approach in Treating Acute Spinal Cord Injuries	31/10/23
Kringle Pharma, Inc. Announces Publication of Preclinical Results from Joint Research with Keio University on Severe Spinal Cord Injury	30/10/23
Kringle Pharma, Inc. Announces Last Patient Out in Phase 3 Study of KP-100IT for the Treatment of Acute Spinal Cord Injury	02/10/23
Kringle Pharma, Inc. announced that it has received ¥1.242 million in funding from Barclays Bank PLC (Tokyo Branch)	04/09/23
Kringle Pharma, Inc. Provides Earnings Guidance for the Fiscal Year Ending September 30, 2023	30/08/23
Kringle Pharma, Inc. announced that it expects to receive ¥1.242 million in funding from Barclays Bank PLC (Tokyo Branch)	14/08/23
Kringle Pharma, Inc. Provides Earnings Guidance for the Fiscal Year Ending September 30, 2023	30/05/23
Kringle Pharma Completes Patient Enrollment for Acute Spinal Cord Injury Treatment	14/04/23
Kringle Pharma, Inc. Announces Last Patient Enrolled in Phase Iii Study for the Treatment of Acute Spinal Cord Injury	13/04/23
Kringle Pharma Files Patent Application for Spinal Cord Injury Treatment	14/03/23
Kringle Pharma, Inc. Announces Patent Application Claims Priority for the Treatment of Chronic Spinal Cord Injury	13/03/23
Kringle Pharma, Inc. Provides Earnings Guidance for the Fiscal Year Ending September 30, 2023	28/02/23
Bank of Japan's Dovish Policy Bolsters Japanese Shares; Shionogi Proceeds with Pediatric Trial of COVID-19 Vaccine	18/01/23
Kringle Pharma Enrolls Initial Candidate in Clinical Study for Vocal Impairment Treatment	18/01/23
Kringle Pharma, Inc. Announces First Patient Enrollment in Phase III Clinical Study for the Treatment of Vocal Fold Scar	17/01/23
Kringle Pharma, Inc. Provides Update on Progress of Phase 3 Clinical Trial in Patients with Acute Spinal Cord Injury	13/01/23
Kringle Pharma, Inc. Provides Consolidated Earnings Guidance for Year Ending September 30, 2023	01/12/22

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Kringle Pharma, Inc.

Actions

4884

JP3270790003

Autres langues

Filtres